Drug Profile
MK 3328
Alternative Names: [18F]MK-3328; MK-3328Latest Information Update: 02 Oct 2021
Price :
$50
*
At a glance
- Originator Merck & Co
- Class Antidementias; Fluorine compounds; Imaging agents; Oxazoles; Pyridines; Radiopharmaceutical diagnostics; Small molecules
- Mechanism of Action
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Alzheimer's disease
Most Recent Events
- 16 Jul 2016 No recent reports of development identified for phase-I development in Alzheimer's-disease(Diagnosis) in Belgium (IV, Injection)
- 06 Aug 2009 Phase-I clinical trials in Alzheimer's disease in Belgium (IV)